A Phase 2 interventional study of DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) in Autism Spectrum Disorder and ASD, sponsored by Definium Therapeutics US, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 619th largest by enrollment of the 658 interventional ones that give a count, is one of 32 that started in 2025, is one of 101 in phase 2, and was the 737th registered.
1,729 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 1 more country
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 300 take children under 18; 92 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 522 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
Definium Therapeutics US, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Definium Therapeutics US, Inc. has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
67 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
This study will enroll approximately twenty adults with Autism Spectrum Disorder (ASD) aged 18 to 65 years of age.
This is a multi-center, open-label study to evaluate the effects after a single administration of DT402 to adults with ASD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA
Drug: DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA
Also known as: MM402, R-MDMA, MDMA
Change from Baseline in 11-point Numerical Rating Scale (NRS) scores
The NRS is an 11-point PRO scale used to measure the severity or intensity of effects from 0 (no effect) to 10 (high severity or intensity of effect). It consists of various items related to both positive and negative effects in the autism patient population.
Time frame: Baseline, pre-dose and 2, 4, 6, 8, and 24 hours post-dose and day 15
Subjective 5-question Drug Effects Questionnaire (DEQ) scores
The Drug Effects Questionnaire is used in studies to assess the participant's acute subjective effects after ingesting substances. It consists of 5 PRO items. The analog scale of responses ranges from "not at all" to "extremely." The score is determined by the distance between the left anchor point and the participant's mark on the line. Each item is scored separately.
Time frame: 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Plasma concentrations
Maximum Plasma Concentration \[Cmax\] of DT402 in the blood.
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Parameters (Cmax)
Maximum concentration (Cmax).
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Parameters (Tmax)
Time to maximum concentration (Tmax).
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Parameters (t1/2)
Time to maximum concentration half-life (t1/2).
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Parameters (AUC0-inf)
Area under the concentration curve from time 0 to infinity (AUC0-inf).
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Pharmacokinetic Parameters (AUC0-24h)
Area under the concentration curve from time 0 to 24 hour (AUC0-24h).
Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose
Ran from Dec 2025 to primary completion in Sep 2026, 9 months.
Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 52. This study's 9 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Aug 2027 → Sep 2026 and completion Aug 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Definium Therapeutics US, Inc.